Form D · Pharmaceuticals
Eyebiotech Ltd
Holborn, London, X0 · CIK 0001878733
Offering snapshot reported Aug 19, 2021 · SEC filing
- Reported sold
- $486 Offering amount: $486
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 19, 2021 | Initial | $486 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-410579
Source: Form D, filed Aug 19, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Catherine Elizabeth Bingham | Director |
| James Allister John Costine | Director |
| David Robert Guyer | Executive |
| Michael Jay Ross | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
International Building, 71 Kingsway
Holborn, London, X0, WC2 6ST
Holborn, London, X0, WC2 6ST